NASDAQ:ESRX - Express Scripts Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$76.80 -0.21 (-0.27 %)
(As of 05/25/2018 01:02 AM ET)
Previous Close$76.80
Today's Range$75.69 - $77.11
52-Week Range$55.80 - $85.07
Volume1.49 million shs
Average Volume4.77 million shs
Market Capitalization$43.67 billion
P/E Ratio10.82
Dividend YieldN/A
Beta0.98

About Express Scripts (NASDAQ:ESRX)

Express Scripts logoExpress Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services. This segment also provides Medicare, Medicaid, and health insurance marketplace products; Express Scripts SafeGuardRx, a suite of solutions targeting the therapy classes that pose clinical challenges and budgetary threat to its clients; and Inside Rx, a program that provide affordable access to medication for uninsured and underinsured individuals. Its Other Business Operations segment distributes specialty pharmaceuticals and medical supplies, including injectable and infusible pharmaceuticals and medications to treat specialty and rare/orphan diseases. This segment also provides medical benefit management solutions for radiology, cardiology, musculoskeletal disorders, sleep disorders, post-acute care, genetic lab, specialty pharmacy, and medical oncology. The company serves managed care organizations, health insurers, third-party administrators, employers, union-sponsored benefit plans, workers' compensation plans, government health programs, providers, clinics, hospitals, and others. As of December 31, 2017, it operated 4 automated dispensing home delivery pharmacies; 1 non-automated dispensing home delivery pharmacy; 7 non-dispensing order processing centers; 5 patient contact centers; 9 specialty home delivery pharmacies; and 34 specialty branch pharmacies. The company was formerly known as Aristotle Holding, Inc. and changed its name to Express Scripts Holding Company in April 2012. Express Scripts Holding Company was founded in 1986 and is headquartered in Saint Louis, Missouri.

Receive ESRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ESRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:ESRX
CUSIP30219G10
Phone314-996-0900

Debt

Debt-to-Equity Ratio0.81
Current Ratio0.69
Quick Ratio0.56

Price-To-Earnings

Trailing P/E Ratio10.82
Forward P/E Ratio8.47
P/E Growth0.98

Sales & Book Value

Annual Sales$100.06 billion
Price / Sales0.43
Cash Flow$10.3644 per share
Price / Cash7.41
Book Value$32.84 per share
Price / Book2.34

Profitability

EPS (Most Recent Fiscal Year)$7.10
Net Income$4.52 billion
Net Margins4.59%
Return on Equity25.41%
Return on Assets8.28%

Miscellaneous

Employees26,600
Outstanding Shares561,720,000

Express Scripts (NASDAQ:ESRX) Frequently Asked Questions

What is Express Scripts' stock symbol?

Express Scripts trades on the NASDAQ under the ticker symbol "ESRX."

How will Express Scripts' stock buyback program work?

Express Scripts announced that its Board of Directors has authorized a share repurchase plan on Wednesday, December 20th 2017, which authorizes the company to repurchase 45,000,000 shares, according to EventVestor. This repurchase authorization authorizes the company to buy shares of its stock through open market purchases. Shares repurchase plans are typically an indication that the company's board of directors believes its stock is undervalued.

How were Express Scripts' earnings last quarter?

Express Scripts (NASDAQ:ESRX) announced its quarterly earnings data on Wednesday, May, 2nd. The company reported $1.77 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $1.76 by $0.01. The business had revenue of $24.77 billion for the quarter, compared to the consensus estimate of $24.80 billion. Express Scripts had a net margin of 4.59% and a return on equity of 25.41%. The firm's revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.33 EPS. View Express Scripts' Earnings History.

When is Express Scripts' next earnings date?

Express Scripts is scheduled to release their next quarterly earnings announcement on Tuesday, July, 24th 2018. View Earnings Estimates for Express Scripts.

What guidance has Express Scripts issued on next quarter's earnings?

Express Scripts updated its FY18 earnings guidance on Wednesday, May, 2nd. The company provided earnings per share (EPS) guidance of $9.00-9.14 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $9.33.

What price target have analysts set for ESRX?

19 brokerages have issued 12-month target prices for Express Scripts' shares. Their forecasts range from $57.00 to $101.00. On average, they expect Express Scripts' share price to reach $82.3929 in the next twelve months. View Analyst Ratings for Express Scripts.

What are Wall Street analysts saying about Express Scripts stock?

Here are some recent quotes from research analysts about Express Scripts stock:
  • 1. According to Zacks Investment Research, "Express Scripts recently announced that its biggest customer and leading health insurer Anthem is not likely to extend its PBM agreement with Express Scripts anymore. Persistent drug pricing issue is also anticipated to affect the stock. Moreover, the company faces stiff competition, which raises concern. The company recently announced that it is getting acquired by Cigna Corporation, a global health insurance company. However, it has been benefitting from a rise in patient claims and strong customer retention. Express Scripts’ solid guidance for 2018 holds promise. Express Scripts' pharmacy-benefit management segment (PBM) coupled with recently-acquired eviCore's complementary medical-benefit solutions is likely to build a comprehensive PBM solution worldwide. In the past six months, Express Scripts has outperformed the industry in terms of price." (5/1/2018)
  • 2. Maxim Group analysts commented, "Cigna Corp (CI – NR) agreed to acquire ESRX for $54B, with per-share consideration of $48.75 in cash and 0.2434 shares of CI stock. CI also agreed to assume roughly $13B of net debt from ESRX." (3/8/2018)

Are investors shorting Express Scripts?

Express Scripts saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 12,982,101 shares, an increase of 23.8% from the April 30th total of 10,485,277 shares. Based on an average trading volume of 4,445,861 shares, the short-interest ratio is presently 2.9 days. Approximately 2.3% of the shares of the company are sold short.

Who are some of Express Scripts' key competitors?

Who are Express Scripts' key executives?

Express Scripts' management team includes the folowing people:
  • Mr. Timothy C. Wentworth, CEO, Pres & Director (Age 58)
  • Mr. James M. Havel, Exec. VP & CFO (Age 63)
  • Mr. David A. Queller, Sr. VP of Sales & Account Management (Age 49)
  • Ms. Christine Houston, Exec. VP of Strategic Integrations (Age 55)
  • Mr. Everett Neville, Exec. VP of Strategy, Supply Chain & Specialty (Age 53)

Has Express Scripts been receiving favorable news coverage?

News stories about ESRX stock have trended somewhat positive on Thursday, Accern reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Express Scripts earned a news sentiment score of 0.08 on Accern's scale. They also gave headlines about the company an impact score of 44.94 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Express Scripts' major shareholders?

Express Scripts' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.21%), Barrow Hanley Mewhinney & Strauss LLC (2.56%), Northern Trust Corp (1.81%), Massachusetts Financial Services Co. MA (1.28%), Dimensional Fund Advisors LP (1.15%) and LSV Asset Management (0.91%). Company insiders that own Express Scripts stock include Christine Houston, Christopher A Mcginnis, Everett Neville, Glen D Stettin, Phyllis S Anderson, Timothy C Wentworth and Woodrow A Myers Jr. View Institutional Ownership Trends for Express Scripts.

Which major investors are selling Express Scripts stock?

ESRX stock was sold by a variety of institutional investors in the last quarter, including Veritas Asset Management LLP, Barrow Hanley Mewhinney & Strauss LLC, OppenheimerFunds Inc., Manning & Napier Group LLC, BlackRock Inc., Schwab Charles Investment Management Inc., Pzena Investment Management LLC and Schroder Investment Management Group. Company insiders that have sold Express Scripts company stock in the last year include Christine Houston, Everett Neville, Glen D Stettin, Phyllis S Anderson and Woodrow A Myers Jr. View Insider Buying and Selling for Express Scripts.

Which major investors are buying Express Scripts stock?

ESRX stock was bought by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, State of New Jersey Common Pension Fund D, Smith Asset Management Group LP, O Shaughnessy Asset Management LLC, Mackay Shields LLC, Massachusetts Financial Services Co. MA, Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Express Scripts.

How do I buy shares of Express Scripts?

Shares of ESRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Express Scripts' stock price today?

One share of ESRX stock can currently be purchased for approximately $76.80.

How big of a company is Express Scripts?

Express Scripts has a market capitalization of $43.67 billion and generates $100.06 billion in revenue each year. The company earns $4.52 billion in net income (profit) each year or $7.10 on an earnings per share basis. Express Scripts employs 26,600 workers across the globe.

How can I contact Express Scripts?

Express Scripts' mailing address is ONE EXPRESS WAY, SAINT LOUIS MO, 63121. The company can be reached via phone at 314-996-0900 or via email at [email protected]


MarketBeat Community Rating for Express Scripts (ESRX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  703 (Vote Outperform)
Underperform Votes:  494 (Vote Underperform)
Total Votes:  1,197
MarketBeat's community ratings are surveys of what our community members think about Express Scripts and other stocks. Vote "Outperform" if you believe ESRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Express Scripts (NASDAQ:ESRX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Express Scripts in the last 12 months. Their average twelve-month price target is $82.3929, suggesting that the stock has a possible upside of 7.28%. The high price target for ESRX is $101.00 and the low price target for ESRX is $57.00. There are currently 3 sell ratings, 11 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.112.112.112.00
Ratings Breakdown: 3 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
7 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
5 Sell Rating(s)
10 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $82.3929$81.8214$78.6786$69.1667
Price Target Upside: 7.28% upside1.33% upside0.80% downside13.09% upside

Express Scripts (NASDAQ:ESRX) Consensus Price Target History

Price Target History for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/17/2018Robert W. BairdSet Price TargetBuy$92.00LowView Rating Details
5/3/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$84.00 ➝ $83.00HighView Rating Details
5/3/2018Leerink SwannLower Price TargetMarket Perform$90.00 ➝ $80.00MediumView Rating Details
3/12/2018Sanford C. BernsteinUpgradeUnderperform ➝ Market PerformMediumView Rating Details
3/9/2018Wells Fargo & CoUpgradeUnderperform ➝ Market PerformLowView Rating Details
3/8/2018Raymond JamesUpgradeUnderperform ➝ Market PerformLowView Rating Details
3/8/2018MizuhoSet Price TargetHold$96.00LowView Rating Details
3/8/2018William BlairDowngradeOutperform ➝ Market PerformLowView Rating Details
3/8/2018Jefferies GroupDowngradeBuy ➝ Hold$91.00HighView Rating Details
3/8/2018Maxim GroupDowngradeBuy ➝ HoldHighView Rating Details
2/27/2018Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$77.00MediumView Rating Details
1/31/2018Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$68.00LowView Rating Details
1/12/2018SunTrust BanksReiterated RatingBuy$95.00LowView Rating Details
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$78.00LowView Rating Details
12/21/2017Needham & Company LLCReiterated RatingHoldLowView Rating Details
12/4/2017Deutsche BankInitiated CoverageBuy$75.00HighView Rating Details
10/9/2017UBSDowngradeMarket Perform ➝ UnderperformN/AView Rating Details
8/10/2017Morgan StanleyBoost Price TargetUnderweight$52.00 ➝ $57.00LowView Rating Details
6/9/2017CowenReiterated RatingOutperform$83.00LowView Rating Details
4/26/2017Edward JonesDowngradeBuy ➝ HoldHighView Rating Details
3/29/2017ArgusReiterated RatingHoldLowView Rating Details
2/16/2017Credit Suisse GroupReiterated RatingBuy$85.00N/AView Rating Details
2/14/2017OppenheimerReiterated RatingHoldN/AView Rating Details
6/1/2016WedbushReiterated RatingNeutralN/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Express Scripts (NASDAQ:ESRX) Earnings History and Estimates Chart

Earnings by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ:ESRX) Earnings Estimates

2018 EPS Consensus Estimate: $8.78
2019 EPS Consensus Estimate: $9.19
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20185$1.46$1.76$1.69
Q2 20185$1.90$2.23$2.14
Q3 20185$2.09$2.48$2.35
Q4 20185$2.31$2.69$2.59
Q1 20193$1.58$2.08$1.83
Q2 20193$2.09$2.34$2.21
Q3 20193$2.26$2.54$2.43
Q4 20192$2.70$2.76$2.73

Express Scripts (NASDAQ ESRX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/23/2018$2.21N/AView Earnings Details
5/2/2018Q1 2018$1.76$1.77$24.8020 billion$24.7694 billionViewN/AView Earnings Details
2/27/2018Q4 2017$2.09$2.16$25.0710 billion$25.3790 billionViewN/AView Earnings Details
10/24/2017Q3 2017$1.90$1.90$25.6827 billion$24.6834 billionViewN/AView Earnings Details
7/25/2017Q2 2017$1.71$1.73$25.5249 billion$25.3475 billionViewN/AView Earnings Details
4/24/2017Q1 17$1.32$1.33$24.9516 billion$24.6549 billionViewN/AView Earnings Details
2/14/2017Q4 2016$1.8660$1.88$26.31 billion$24.90 billionViewListenView Earnings Details
10/25/2016Q3$1.74$1.74$25.4846 billion$25.41 billionViewListenView Earnings Details
7/25/2016Q216$1.57$1.57$25.42 billion$25.20 billionViewListenView Earnings Details
4/25/2016Q1$1.22$1.22$25.20 billion$24.80 billionViewListenView Earnings Details
2/16/2016Q4$1.56$1.56$26.58 billion$26.18 billionViewListenView Earnings Details
10/27/2015Q315$1.44$1.45$26.38 million$25.22 millionViewListenView Earnings Details
7/28/2015Q215$1.40$1.44$26.13 billion$25.4540 billionViewListenView Earnings Details
4/28/2015Q115$1.10$1.10$24.34 billion$24.90 billionViewListenView Earnings Details
2/23/2015Q414$1.38$1.39$25.68 billion$26.31 billionViewListenView Earnings Details
10/28/2014Q314$1.29$1.29$24.93 billion$25.78 billionViewListenView Earnings Details
7/29/2014Q214$1.22$1.23$24.42 billion$25.1110 billionViewListenView Earnings Details
4/29/2014Q114$1.01$0.99$23.81 billion$23.6850 billionViewListenView Earnings Details
2/20/2014Q413$1.12$1.12$25.49 billion$25.78 billionViewN/AView Earnings Details
10/25/2013Q313$1.08$1.08$25.01 billion$25.9160 billionViewListenView Earnings Details
7/29/2013Q2 2013$1.10$1.12$25.51 billion$26.40 billionViewListenView Earnings Details
4/29/2013Q1 2013$0.97$0.99$25.55 billion$26.0630 billionViewListenView Earnings Details
2/18/2013Q4 2012$1.04$1.05$27.24 billion$27.41 billionViewListenView Earnings Details
11/5/2012Q312$0.99$1.02$27.48 billion$27.00 billionViewN/AView Earnings Details
8/7/2012$0.82$0.88ViewN/AView Earnings Details
5/10/2012$0.77$0.73ViewN/AView Earnings Details
2/22/2012$0.85$0.82ViewN/AView Earnings Details
10/25/2011$0.77$0.79ViewN/AView Earnings Details
7/21/2011$0.69$0.71ViewN/AView Earnings Details
4/26/2011$0.69$0.66ViewN/AView Earnings Details
2/16/2011$0.70$0.71ViewN/AView Earnings Details
10/27/2010Q3 2010$0.65$0.65ViewN/AView Earnings Details
7/28/2010Q2 2010$0.59$0.60ViewN/AView Earnings Details
4/28/2010Q1 2010$0.55$0.55ViewN/AView Earnings Details
2/24/2010Q4 2009$0.45$0.49ViewN/AView Earnings Details
10/28/2009Q3 2009$0.41$0.40ViewN/AView Earnings Details
7/29/2009Q2 2009$0.44$0.44ViewN/AView Earnings Details
4/29/2009Q1 2009$0.41$0.43ViewN/AView Earnings Details
2/25/2009Q4 2008$0.42$0.41ViewN/AView Earnings Details
10/30/2008Q3 2008$0.39$0.41ViewN/AView Earnings Details
7/30/2008Q2 2008$0.36$0.38ViewN/AView Earnings Details
4/29/2008Q1 2008$0.34$0.35ViewN/AView Earnings Details
2/21/2008Q4 2007$0.32$0.34ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Express Scripts (NASDAQ:ESRX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Express Scripts (NASDAQ ESRX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.79%
Institutional Ownership Percentage: 85.82%
Insider Trading History for Express Scripts (NASDAQ:ESRX)
Institutional Ownership by Quarter for Express Scripts (NASDAQ:ESRX)

Express Scripts (NASDAQ ESRX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2018Christine HoustonInsiderSell19,889$76.69$1,525,287.41View SEC Filing  
3/1/2018Everett NevilleVPSell4,895$75.26$368,397.70View SEC Filing  
1/11/2018Glen D StettinVPSell3,449$81.00$279,369.0033,715View SEC Filing  
1/2/2018Glen D StettinVPSell3,448$76.00$262,048.00View SEC Filing  
12/15/2017Christine HoustonVPSell10,104$70.08$708,088.3287,400View SEC Filing  
11/1/2017Phyllis S. AndersonVPSell643$62.37$40,103.91View SEC Filing  
10/31/2017Timothy C WentworthCEOBuy8,000$61.13$489,040.0098,628View SEC Filing  
9/11/2017Woodrow A Myers JrDirectorSell3,900$63.93$249,327.0011,500View SEC Filing  
9/8/2017Phyllis S AndersonVPSell578$63.13$36,489.1410,530View SEC Filing  
8/23/2017Everett NevilleVPSell1,163$61.48$71,501.2418,232View SEC Filing  
5/19/2017Phyllis S AndersonVPSell1,100$60.08$66,088.0011,108View SEC Filing  
3/1/2017Everett NevilleSVPSell2,352$70.16$165,016.3211,287View SEC Filing  
1/3/2017Everett NevilleVPSell1,123$69.41$77,947.4312,712View SEC Filing  
9/14/2016Woodrow A Myers JrDirectorSell12,036$70.40$847,334.4014,918View SEC Filing  
9/12/2016Christopher A McginnisVPSell1,785$70.77$126,324.454,955View SEC Filing  
5/10/2016Everett NevilleVPSell800$74.11$59,288.0013,835View SEC Filing  
4/29/2016Mahon Thomas P MacDirectorSell5,482$73.93$405,284.2655,689View SEC Filing  
3/10/2016Christopher A McginnisVPSell579$68.56$39,696.246,508View SEC Filing  
3/7/2016Phyllis S AndersonVPSell614$71.14$43,679.964,346View SEC Filing  
2/29/2016Everett NevilleVPSell4,323$71.00$306,933.0011,126View SEC Filing  
6/9/2015Gary WimberlyVPSell1,644$87.14$143,258.16View SEC Filing  
6/1/2015Gary WimberlyVPSell46,069$86.15$3,968,844.35View SEC Filing  
3/2/2015Glen D StettinVPSell2,674$84.39$225,658.86View SEC Filing  
2/25/2015Glen D StettinVPSell27,603$87.55$2,416,642.65View SEC Filing  
12/2/2014Keith J EblingVPSell10,000$84.25$842,500.00View SEC Filing  
12/1/2014Steven B MillerVPSell4,896$83.57$409,158.72View SEC Filing  
11/28/2014Glen D StettinVPSell10,800$82.96$895,968.00View SEC Filing  
11/17/2014John O ParkerDirectorSell25,822$78.75$2,033,482.50View SEC Filing  
11/7/2014Maura C BreenDirectorSell13,128$77.80$1,021,358.40View SEC Filing  
9/5/2014Edward B IgnaczakEVPSell9,886$75.28$744,218.08View SEC Filing  
8/28/2014Seymour SternbergDirectorSell15,508$74.12$1,149,452.96View SEC Filing  
8/25/2014Keith J EblingVPSell10,000$75.50$755,000.00View SEC Filing  
8/5/2014Gary G BenanavDirectorSell12,694$70.82$898,989.08View SEC Filing  
8/5/2014Sara E WadeVPSell20,000$70.44$1,408,800.00View SEC Filing  
8/4/2014David A NortonVPSell1,276$71.02$90,621.52View SEC Filing  
8/1/2014Maura C BreenDirectorSell12,694$69.94$887,818.36View SEC Filing  
6/13/2014George PazCEOSell681,508$71.21$48,530,184.68View SEC Filing  
3/11/2014Keith EblingVPSell25,721$78.69$2,023,985.4922,222View SEC Filing  
3/10/2014Patrick McnameeCOOSell68,425$78.28$5,356,309.0012,421View SEC Filing  
3/10/2014Steven MillerVPSell12,664$77.96$987,285.4421,417View SEC Filing  
3/7/2014Keith EblingVPSell295,367$77.29$22,828,915.4328,460View SEC Filing  
1/9/2014Nicholas LahowchicDirectorSell7,650$72.00$550,800.0024,903View SEC Filing  
12/26/2013Nicholas LahowchicDirectorSell12,694$70.00$888,580.0024,903View SEC Filing  
11/5/2013Mahon Thomas MacDirectorSell10,251$63.20$647,863.2039,881View SEC Filing  
9/9/2013Maura C BreenDirectorSell10,527$64.12$674,991.24View SEC Filing  
9/4/2013Woodrow Myers, Jr.DirectorSell7,128$64.66$460,896.489,698View SEC Filing  
7/19/2013Nicholas LahowchicDirectorSell20,377$66.26$1,350,180.02View SEC Filing  
6/11/2013Woodrow A Myers JrDirectorSell1,750$62.57$109,497.50View SEC Filing  
5/28/2013Woodrow A Myers JrDirectorSell2,000$63.75$127,500.00View SEC Filing  
5/15/2013Jeffrey HallCFOSell13,307$61.13$813,456.91View SEC Filing  
5/8/2013Woodrow A Myers JrDirectorSell13,462$61.22$824,143.64View SEC Filing  
5/1/2013Keith J EblingEVPSell59,494$59.58$3,544,652.52View SEC Filing  
4/30/2013Patrick McnameeCOOSell271,972$59.65$16,223,129.80View SEC Filing  
3/14/2013Mahon Thomas P MacDirectorBuy5,000$59.58$297,900.00View SEC Filing  
9/4/2012Jeffrey HallCFOSell75,000$62.81$4,710,750.00View SEC Filing  
8/8/2012Edward B IgnaczakEVPSell115,466$59.33$6,850,597.78View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Express Scripts (NASDAQ ESRX) News Headlines

Source:
DateHeadline
New Drug Costs Are Still High, But Putting Prices In TV Ads Offers Little ValueNew Drug Costs Are Still High, But Putting Prices In TV Ads Offers Little Value
finance.yahoo.com - May 23 at 8:04 AM
Express Scripts (ESRX) Expected to Announce Quarterly Sales of $25.34 BillionExpress Scripts (ESRX) Expected to Announce Quarterly Sales of $25.34 Billion
www.americanbankingnews.com - May 20 at 2:12 AM
$2.23 EPS Expected for Express Scripts (ESRX) This Quarter$2.23 EPS Expected for Express Scripts (ESRX) This Quarter
www.americanbankingnews.com - May 18 at 7:29 PM
Notable Friday Option Activity: ACXM, ESRX, ADBENotable Friday Option Activity: ACXM, ESRX, ADBE
www.nasdaq.com - May 18 at 5:58 PM
U.S. FDA approves Amgen drug for prevention of migrainesU.S. FDA approves Amgen drug for prevention of migraines
finance.yahoo.com - May 18 at 9:04 AM
Express Scripts (ESRX) Given a $92.00 Price Target at Robert W. BairdExpress Scripts (ESRX) Given a $92.00 Price Target at Robert W. Baird
www.americanbankingnews.com - May 17 at 2:59 PM
Express Scripts to remain in St. Louis County, filing saysExpress Scripts to remain in St. Louis County, filing says
finance.yahoo.com - May 16 at 6:03 PM
Express Scripts (ESRX) Short Interest UpdateExpress Scripts (ESRX) Short Interest Update
www.americanbankingnews.com - May 13 at 1:40 AM
Express Scripts (ESRX) Downgraded by BidaskClub to SellExpress Scripts (ESRX) Downgraded by BidaskClub to Sell
www.americanbankingnews.com - May 11 at 8:05 PM
Trump assails high drug prices, avoids direct hit on industryTrump assails high drug prices, avoids direct hit on industry
finance.yahoo.com - May 11 at 6:24 PM
Express Scripts and CVS among those gaining after Trump speechExpress Scripts and CVS among those gaining after Trump speech
seekingalpha.com - May 11 at 3:52 PM
The Trump administration has a little-known practice in the pharma industry in its crosshairs (ESRX)The Trump administration has a little-known practice in the pharma industry in its crosshairs (ESRX)
www.msn.com - May 11 at 8:25 AM
Innovative Value-based SafeGuardRx® Program Delivers Better Care at Lower Cost for Express Scripts Patients and Plan SponsorsInnovative Value-based SafeGuardRx® Program Delivers Better Care at Lower Cost for Express Scripts' Patients and Plan Sponsors
finance.yahoo.com - May 10 at 5:58 PM
ESRX Makes Notable Cross Below Critical Moving AverageESRX Makes Notable Cross Below Critical Moving Average
www.nasdaq.com - May 8 at 6:00 PM
Express Scripts Vulnerable Ahead Of President Trumps New Policy OutlinesExpress Scripts Vulnerable Ahead Of President Trump's New Policy Outlines
seekingalpha.com - May 8 at 8:00 AM
How Tampa Bay’s startup community compares to the rest of the worldHow Tampa Bay’s startup community compares to the rest of the world
finance.yahoo.com - May 7 at 8:04 AM
Equities Analysts Offer Predictions for Express Scripts FY2018 Earnings (ESRX)Equities Analysts Offer Predictions for Express Scripts' FY2018 Earnings (ESRX)
www.americanbankingnews.com - May 7 at 4:01 AM
Q3 2018 EPS Estimates for Express Scripts Reduced by Analyst (ESRX)Q3 2018 EPS Estimates for Express Scripts Reduced by Analyst (ESRX)
www.americanbankingnews.com - May 7 at 3:23 AM
Q2 2018 EPS Estimates for Express Scripts Reduced by Jefferies Group (ESRX)Q2 2018 EPS Estimates for Express Scripts Reduced by Jefferies Group (ESRX)
www.americanbankingnews.com - May 7 at 2:16 AM
Express Scripts to Post Q2 2018 Earnings of $2.23 Per Share, Leerink Swann Forecasts (ESRX)Express Scripts to Post Q2 2018 Earnings of $2.23 Per Share, Leerink Swann Forecasts (ESRX)
www.americanbankingnews.com - May 7 at 2:16 AM
Express Scripts (ESRX) Downgraded to "Hold" at BidaskClubExpress Scripts (ESRX) Downgraded to "Hold" at BidaskClub
www.americanbankingnews.com - May 5 at 12:29 AM
'60 Minutes' report to focus on price of Mallinckrodt dru...'60 Minutes' report to focus on price of Mallinckrodt dru...
finance.yahoo.com - May 4 at 5:51 PM
Oppenheimer Comments on Express Scripts Q2 2018 Earnings (ESRX)Oppenheimer Comments on Express Scripts' Q2 2018 Earnings (ESRX)
www.americanbankingnews.com - May 4 at 8:50 AM
Q2 2018 Earnings Estimate for Express Scripts Issued By William Blair (ESRX)Q2 2018 Earnings Estimate for Express Scripts Issued By William Blair (ESRX)
www.americanbankingnews.com - May 4 at 8:50 AM
Express Scripts (ESRX) PT Lowered to $83.00Express Scripts (ESRX) PT Lowered to $83.00
www.americanbankingnews.com - May 4 at 12:23 AM
Express Scripts (ESRX) PT Lowered to $80.00Express Scripts (ESRX) PT Lowered to $80.00
www.americanbankingnews.com - May 3 at 8:34 PM
Cigna first quarter profit beats but shares drop on Express Scripts worriesCigna first quarter profit beats but shares drop on Express Scripts worries
www.reuters.com - May 3 at 5:39 PM
Cigna CEO: Theres a lot of noise around regulatory concern of Express Scripts dealCigna CEO: There's a lot of noise around regulatory concern of Express Scripts deal
www.cnbc.com - May 3 at 1:21 PM
Inside Rx, a Prescription Savings Program from Express Scripts, Expands List of Discounted Brand-Name MedicationsInside Rx, a Prescription Savings Program from Express Scripts, Expands List of Discounted Brand-Name Medications
www.prnewswire.com - May 3 at 9:36 AM
Health insurer Cigna quarterly profit rises 53 pctHealth insurer Cigna quarterly profit rises 53 pct
finance.yahoo.com - May 3 at 8:00 AM
Health insurer Cigna profit beats estimatesHealth insurer Cigna profit beats estimates
finance.yahoo.com - May 3 at 8:00 AM
$24.76 Billion in Sales Expected for Express Scripts (ESRX) This Quarter$24.76 Billion in Sales Expected for Express Scripts (ESRX) This Quarter
www.americanbankingnews.com - May 3 at 4:20 AM
ValuEngine Lowers Express Scripts (ESRX) to HoldValuEngine Lowers Express Scripts (ESRX) to Hold
www.americanbankingnews.com - May 2 at 11:23 PM
Express Scripts (ESRX) Announces  Earnings ResultsExpress Scripts (ESRX) Announces Earnings Results
www.americanbankingnews.com - May 2 at 7:32 PM
Express Scripts (ESRX) Updates FY18 Earnings GuidanceExpress Scripts (ESRX) Updates FY18 Earnings Guidance
www.americanbankingnews.com - May 2 at 6:08 PM
EXPRESS SCRIPTS HOLDING COMPANYEXPRESS SCRIPTS HOLDING COMPANY
www.finanznachrichten.de - May 2 at 5:50 PM
Express Scripts Q1 top line flat; earnings up 14%; cash flow up 51%Express Scripts Q1 top line flat; earnings up 14%; cash flow up 51%
seekingalpha.com - May 2 at 5:50 PM
Express Scripts Updates FY18 Adj. EPS Guidance - Quick FactsExpress Scripts Updates FY18 Adj. EPS Guidance - Quick Facts
www.nasdaq.com - May 2 at 5:50 PM
Express Scripts Announces 2018 First Quarter ResultsExpress Scripts Announces 2018 First Quarter Results
finance.yahoo.com - May 2 at 5:50 PM
Express Scripts Ranked as a Top 50 Inclusive company by DiversityIncExpress Scripts Ranked as a Top 50 Inclusive company by DiversityInc
finance.yahoo.com - May 2 at 5:50 PM
Express Scripts: 1Q Earnings SnapshotExpress Scripts: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 5:50 PM
Express Scripts shares slip after revenue miss, lowered outlookExpress Scripts shares slip after revenue miss, lowered outlook
finance.yahoo.com - May 2 at 5:50 PM
Express Scripts (ESRX) Downgraded to Sell at Zacks Investment ResearchExpress Scripts (ESRX) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 1 at 12:26 PM
$1.76 EPS Expected for Express Scripts (ESRX) This Quarter$1.76 EPS Expected for Express Scripts (ESRX) This Quarter
www.americanbankingnews.com - May 1 at 8:21 AM
Regeneron/Sanofi to cut price of heart drug in Express Scripts dealRegeneron/Sanofi to cut price of heart drug in Express Scripts deal
finance.yahoo.com - May 1 at 8:04 AM
Regeneron And Express Scripts Reach A Deal On Embattled Cholesterol DrugRegeneron And Express Scripts Reach A Deal On Embattled Cholesterol Drug
finance.yahoo.com - May 1 at 8:04 AM
[$$] Sanofi slashes price of wannabe-blockbuster cholesterol drug[$$] Sanofi slashes price of wannabe-blockbuster cholesterol drug
finance.yahoo.com - May 1 at 8:04 AM
Regeneron and Express Scripts announce exclusive pricing ...Regeneron and Express Scripts announce exclusive pricing ...
finance.yahoo.com - May 1 at 8:04 AM
Sanofi/Regeneron cut Praluent drug price in Express Scripts dealSanofi/Regeneron cut Praluent drug price in Express Scripts deal
finance.yahoo.com - May 1 at 8:04 AM
Express Scripts (ESRX) Receives Consensus Recommendation of "Hold" from BrokeragesExpress Scripts (ESRX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - April 30 at 11:36 AM

SEC Filings

Express Scripts (NASDAQ:ESRX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Express Scripts (NASDAQ:ESRX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Express Scripts (NASDAQ ESRX) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.